Compare VTAK & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTAK | XXII |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.3M |
| IPO Year | 2018 | 2011 |
| Metric | VTAK | XXII |
|---|---|---|
| Price | $0.95 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 163.3K | ★ 850.8K |
| Earning Date | 08-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.53 | 69.96 |
| EPS | ★ N/A | N/A |
| Revenue | $442,000.00 | ★ $25,832,530.00 |
| Revenue This Year | $1,170.33 | $370.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3057.14 | N/A |
| 52 Week Low | $0.15 | $0.67 |
| 52 Week High | $4.31 | $11.37 |
| Indicator | VTAK | XXII |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 19.51 |
| Support Level | $0.88 | $0.71 |
| Resistance Level | $1.28 | $1.10 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 53.76 | 3.36 |
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.